Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Targeted therapies have improved outcomes for patients with lung cancer, but the goal needs to be tailoring the right therapy to the right patient, said Ticiana Leal, MD, associate professor, director of the Thoracic Medical Oncology Program, Department of Hematology and Medical Oncology, Emory University School of Medicine.
Transcript
How are targeted therapies and testing to identify the right patient for the right drug improving outcomes for patients with lung cancer?
Targeted therapies have really improved outcomes for patients with lung cancer. And we've seen a publication demonstrating decreased mortality for patients with lung cancer. It coincides with approval of targeted therapies for non–small cell lung cancer. Precision medicine has really changed the treatment paradigm for patients with advanced non–small cell lung cancer.
And certainly, identifying these patients is key. So, performing next-generation sequencing, performing a broad-based panel to really identify these mutations. Some of these mutations are very rare, but when you do a broad-based panel, you can identify more mutations in more patients. Adding tumor tissue plus liquid biopsy may also enhance the ability to find these mutations. I think it's really important to do that, because there are increasing studies showing that might be even actually a strategy that is cost-effective, because what you're doing is, you're selecting patients for the right treatment.
We know targeted therapies are expensive, but if you can tailor the right therapy for the right patient, I think in the end, you're providing better care, improved outcomes for patients, better tolerability, less toxicities. I think there's a component there that the more we do this—and hopefully these studies are better designed to answer that question—we’re also going to be seeing that that is a cost-effective strategy for our patients with advanced non–small cell lung cancer.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis
April 12th 2024New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.
Read More